Ozempic

Novo Nordisk has found the formula to recover the profitability of Ozempic: fire 9,000 employees

by

The Pharmaceutical Novo Nordisk, manufacturer of Ozempic and Wegovy, is living one of the biggest turbulence in its history recent. After losing the favor of investors and a good part of its stock market value in the last year, the company has announced a drastic reduction of workforce that affects 9,000 employees around the world: 11.5% of the total staff. 9,000 layoffs, most in Denmark. Novo Nordisk has confirmed Through a statement the cut of 9,000 jobs in the coming years, a figure that represents 11.5% of its template globally, composed of 78,400 employees. Denmark, a country of origin of the pharmaceutical, will be the country that will receive the greatest impact of that measure, accumulating about 5,000 of the planned dismissals. The firm has not yet specified how layoffs will be distributed in the rest of international venues, since the decision is subject to “to the relevant consultations in accordance with local labor legislation.” The multinational has remarked that “this is a global transformation, and each country, headquarters or region will be affected differently,” underlining the international dimension of its labor adjustment process. Multimillionaire savings and business reorganization. With this cut, the pharmaceutical enhance business lines centered on the Research for new treatments For diabetes and obesity, putting greater emphasis on commercial initiatives. It should be remembered that, in origin, both Ozempic and Wegovy were born as a new treatment to enhance insulin generation, but its satiating effects turned out to be much more profitable. Among the objectives mentioned in the official statement include organizational simplification, the increase in speed in decision making and the reallocation of resources towards the strategic fields of the company. According to the statement, Nordisk “must evolve in a market that has become more competitive and consumer oriented”, which implies “a change of mentality and approach that allows us to be faster and faster.” According to published by Reutersthe company would have asked its employees to return to its full -time offices within that same restructuring and optimization plan for its operations. Bursatile bleeding as a trigger. The collapse of the stock market suffered by Novo Nordisk during the last year is the main trigger for the adjustment measure. As published the BBCthe price of your shares was reduced by 60% Since June 2024, losing 430,000 million in stock market capitalization. The situation was especially aggravated on July 30, with a decrease in 23% in a single day After the downward review Growth forecasts and the announcement of the relay in the executive direction. The official presentation of Mike Doustdar as the new CEO of the company has marked the beginning of this stage of changes, which aims to recover the confidence of investors and redefine the corporate culture of the company. Its first measure has had a positive impact on the markets, and after the announcement of the template cuts the value of its shares has increased by 3%. In Xataka | If you want a “miracle” medication to lose weight, you no longer resort to Ozempic: the competition is starting to overcome it Image | Flickr (News Oresund, Chemist4u)

WHO wants to improve access to drugs such as Ozempic. Now they are on their list of essential medicines

by

Ozempicthe treatment against diabetes that reached the fame converted into medication for weight loss has lived for a convulsive years that could have resulted in a “death for success.” The popularity of the drug created a severe supply problem. Now, the World Health Organization (WHO) has taken a new step to improve access to the drug, especially in less favored countries. Updating the list. The (WHO) has up to date its model list of essential medicines (EML). The new list Includes GLP-1 drugswhich emulate the peptide that gives its name to the group, the family of treatments flagging by Ozempic. According to the international organism, this inclusion aims to improve access to the popular drug, especially in countries with less income. The extension covers other drugs, such as treatments against various types of cancer, against cystic fibrosis, psoriasis, hemophilia and other blood -related disorders. In total, the new list now incorporates 523 essential medicines. The extension It also affects the WHO model list of essential pediatric medicines (EMLC), which now has 374 treatments. The “GLP-1 family”. The incorporation of the GLP-1 drugs includes compounds such as semaglutida (the Ozempic base and Wegovy), the dorara and the liraglutid Zepbound and Mounjaro). These types of compounds act as agonists of the hormone receptors that we know as LPG-1, or Peptide similar to type-1 glucagon (although some also work as agonists of other hormones). This hormone is produced and segregated by our body after meals and meets Two key functions. On the one hand, it informs the pancreas of the intake to reinforce insulin production, hence these compounds help people with diabetes. The second function of this peptide is the one that makes these useful drugs to lose weight. The LPG-1 also transmits information to our brain, information that it interprets as the feeling of satiety. Improve access. According to WHO explains in a press releasethese drugs can help people with type 2 diabetes improve their glycemic control, but they are also able to “reduce the risk of cardiovascular and renal complications, favor weight loss and even reduce the risk of premature death, especially if they have renal or cardiac failure ”, a fact that would be based, at least in part, the decision. As details in the international organism, the price of these drugs implies significant access to them. Its inclusion in the list aims to expand this access, prioritizing patients who can benefit the most while fostering competition through genericians capable of bringing these medications to primary care, “especially in unattended areas.” “A large part of the direct spending of families in noncommunicable diseases is destined for medicines (…). To offer equitable access to essential medicines, an equal response of health systems, a strong political will, multisectoral cooperation and programs focused on people who allow everyone,” detailed in the press release Deusdedit Mumbangizi, Director of Policies and Standards for Medicines and Health Products of the WHO. Expanding in the fight against cancer. The expansion of WHO lists also include several cancer treatments, including several antineoplastic, drugs that seek to avoid the formation of growth that can become cancerous or neoplasms. Among these drugs are inhibitors of the immune control point PD-1/PD-L1, which help our immune system To recognize and attack with cancer cells. In Xataka | China is the great candy of pharmaceutical thinning. And there is a wild race for selling the new ozempic Image | Chemist4u / Yann Forget

The great alternative to Ozempic is LPG-1

by

Despite the great promise to quickly lose weight thanks to a minimum puncture, many people still reject the idea of injecting medicines such as Ozempic either Wegovy. In response, great pharmaceuticals refine their strategies with based on pill versions In the GLP-1 receiver. However, the first figures raise an awkward question: What will be willing to sacrifice patients in exchange for not pricking? In the test phase. The Eli Lillly company has presented the results of its clinical trial with Orforglipron, a daily pill designed to induce weight loss. According to data published by The Washington PostThe participants who took the highest dose reduced their body weight on average after 72 weeks, which is equivalent to about 12 kilos, compared to less than 1 % in the placebo group. It is a clinically significant result, but lower than that reached with its strut -in -lawy -led drugs – commercialized as Mounjaro or Zepbound -, with which in a previous trial a 22.5 % weight loss was achieved in the same period. The company said it will request the regulatory approval before the end of the year and trusts that the comfort of the pill compensates its lower power. Pfizer was the first. The race for the GLP-1 pills is not exclusive to Lilly and Novo. As we collected in Xatakathe American pharmacist Pfizer has announced advances in the development of Danuglipron, an agonist of the GLP-1 receiver who, unlike Ozempic, Wegovy or Zepbound, would be administered only orally. The drug is in a new phase of clinical trials to evaluate its safety and pharmacokinetics, with the aim of adjusting it as a daily taking treatment. According to the company, the tests have already included 1,400 healthy adults in an open and random essay. Preliminary data promoted Pfizer’s actions 2 % in the stock market, But analysts cited by Xatakalike Uumer Raffat for Fortune, warn that advances seem “tentative” and that, in the best case, the medicine would reach the market in 2028. There are more bets. The Ozempic and Wegovy manufacturer also does not want to stay out of the transition to the pills. As we have reported in XatakaNovo Nordisk awaits an FDA decision about its oral version of Semaglutida before it ends 2025. In parallel, its candidate Cagrisema – a combination of semaglutida and cagrilintida – achieved in clinical trials an average weight reduction of 22.7 %, slightly below the 25 % that the company had announced as an initial objective. A fact that, although raised, shows that even in the new generation of oral treatments, the power can remain below expectations. Comfort against efficacy. GLP-1 medications have shown unprecedented results in the fight against obesity, but the route of administration marks differences. As they have detailed in Washington Postweekly injection of tirzepatida or semaglutida allows to reach more stable levels of the blood molecule and, with it, greater weight reductions. On the other hand, the oral route requires formulas that resist digestion and are effectively absorbed, which raises technical limitations. In the case of Orforglipron, the consequence is a weight loss lower than that of its injectable equivalents. The big question is whether patients and doctors will be willing to prioritize comfort over effectiveness. For many, a 12 % reduction in body weight remains clinically relevant and can mean substantial improvements in cardiovascular and metabolic health. But in a market in which each percentage point counts, the comparison with 20-22 % of the injections could condition their adoption. A millionaire market with access barriers. The interest in these therapies is not accidental. According to estimates collected by this meansthe global market of obesity medications could exceed 100,000 million dollars annually in 2030. In addition to weight loss, LPG-1 improve glycemic control and reduce cardiovascular risk, which expands its clinical attraction. However, the price remains an obstacle. According to data cited in this mediumOzempic costs around $ 600 per month in the United States, compared to 59 euros in Germany. So the debate for future oral versions is open. A future with more options and more questions. With Lilly, Pfizer and Novo Nordisk preparing their releases, GLP-1 pills could expand the scope of obesity treatments, especially among those who reject injections. But the transition will not be automatic. In a market where efficacy has been the main sales argument, the arrival of more comfortable but potentially less powerful options will force to rethink strategies, prices and expectations. And although the interest is evident, the question remains the same: how much is it worth, for doctors and patients, the simple fact of not having to use a needle? Image | Unspash and Unspash Xataka | If you want a “miracle” medication to lose weight, you no longer resort to Ozempic: the competition is starting to overcome it

Novo Nordisk has been made gold with Ozempic but knows that it will not last forever. So you already have two substitutes

by

The slimming drug market does not stop enlarging but the competition for taking the largest portion in this growing “cake” It is fierce. The American pharmaceutical Ozempic. Now the European company tries to recover its advantage. And he does it with a double ad. Roadmap. Little by little Let’s get to know more details About the drugs that Danish pharmaceuticals Novo Nordisk wants to give relief to Ozempic and Wegovy, their star treatments based on semaglutida. Different compounds, different analogues. Semaglutida is the active compound on which medications such as Ozempic and Wegovy are based. This formula, initially devised as diabetes treatment, works by serving as analogous to the GLP-1 hormone (peptide similar to type 1 glucagon), it is what is known as an agonist of hormone receptors. LPG-1 is a hormone that fulfills two functions in our body by transmitting the message that we have fed on the pancreas, activating insulin production; and to the brain, unleashing the feeling of satiety. This second function is the one that has led to the success of Ozempic and similar drugs transforming into weight loss treatments and thus achieving its present success. The new Danish pharmaceutical formulas are based on compounds that act similarly to the semaglutida, but with characteristics that make them own and, at least in principle, superior. Cagrisema Of the formulas proposed by Novo Nordis, Cagrisema is perhaps the one in a more advanced state of development. The drug is based on the semaglutida and the Cagrilintidaa compound that serves as an analogue of amiline And also of the Calcitoninacting as agonist of some of the receptors of these hormones. Amiline is a hormone similar to insulin, also segregated by the pancreas and also used for glycemic control in our body. Cagrisema therefore works as a double (or triple) analogous, however The first results They were not as positive as some expected. New data. Now we have the remaining data of the essays by the company to derter the efficacy of the drug. According to Explain Reutersthe study data showed a weight reduction of about 23% in overweight adults after 68 weeks; and 16% weight loss among people with diabetes. Those responsible for the company gave data on moderate adverse effects, which affected 79.6% of the participants; and serious, which affected 9.8% (with 6% of patients abandoning the trial). Those responsible expect the arrival of Cagrisema to the market towards the beginning of 2027. Amicretin. Last week Novo Nordisk He also announced The implementation of phase 3 tests of amicretin, one of the compounds designed to contain the legacy of the semaglutida. According to the company itself, this compound is a unimolecular agonist of prolonged action of the GLP-1 receptors and those of the amiline. One of the great novelties is that this formula is being tested not only to evaluate its subcutaneous administration but also its consumption orally. Phase 3 of clinical trials usually seeks to complete and complement the information obtained in previous trials in addition to studying additional issues such as dosage or efficiency compared to other formulas. The other novelty of Novo. In addition to the new formulas, Ozempic has also monopolized attention in the last week. He did it since the European Medicines Agency (EMA) I went on to recommend this drug as treatment for peripheral arterial disease, In Xataka | Generic medications have been trying to site Ozempic for years. And now they have found a shortcut in Canada Image | Chemist4u / News Oresund

China is the great candy of pharmaceutical thinning. And there is a wild race for selling the new ozempic

by

Few would have guessed not so long that a pharmacist focused on the insulin segment would become a company with A higher value than Tesla. Novo Nordisk became the most valuable quoted company in Europe Thanks to the fashion product: Ozempic. This diabetes treatment spun by becoming the Miracle of weight loss that many needed, Despite its side effects. But there are situations that do not last forever and China is about to seize Ozempic tooth in a market with a lot of potential. And they have about twenty biosimilar copies calling the door. Challenging the reign. In recent days we have seen that something strange has happened with Ozempic. By mistake or for a failure in the calculations, Novo Nordisk carries years without paying protection rates of the Ozempic patent in Canada. It is a quota that serves to protect the compound on which the popular Ozempic and Wegovy drugs, the same pharmaceutical drugs. It is something that is allowing local companies to be Finally generic medications based on the peptide similar to LPG-1. It is about the hormone that “mimics” the semagglutide that allows this antidiabetic and thinning effect. The Chinese market rubs your hands. In China, something similar happens. The patents have a life time that allow those who have registered them with that competitive advantage, but after the established period, the ban opens. While in Europe and Japan this patent will expire in 2031, and in 2032 in the United States, the protection of the patent in China It will expire Next year, as we read in South China Morning Post. Lek Consulting is a consultant based in Boston and comments that “China is home to populations with the highest number of diabetic and overweight people, and has become a key battlefield for both global pharmaceutical giants and for local actors.” Montones competitors. According to the SCMP report, in China there are at least 20 biosimilar copies that will compete for this market share, which will generate absolute pressure in the prices of the semaglutida. “The panorama in China is expected to become even more competitive than in the developed markets, where the category of GLP-1 medicines is dominated by large multinational pharmaceuticals,” commented Helen Chen, global co -director of Medical Care and Life Sciences of Le.K. Currently, Novo Nordisk opera In China both with Ozempic and Wegovy, but Eli Lilly also operates in the Chinese market, the American company with a response to the drug that could enter the country thanks to the premises Innovent Biologics. In the summer last year, They announced An expansion plan of more than 200 million euros to expand a plant in Suzhou with which to meet demand in the Asian giant. But, in addition, there are several dozens of drugs that are in advanced phases of clinical trials in China and, as they comment from Le.K., some have potential to compete directly with Novo Nordisk and Eli Lilly products. A very fat cake. That there are so many interested parties is the most normal. China, by overwhelming population numbersit is a huge market for any product, but in this field, we are talking about the second largest pharmaceutical market in the world, with almost 150 million adults with diabetes. It is more than any other country and, according to the International Diabetes Federation, the estimate is that the figure increases to 168 by 2050. But also, in 2021 The Lancet Medical Magazine estimated that 402 million people over 25 years in continental China had obesity. By contextualizing, it is a figure that represents 38% of the population and that reflects the country’s life progress. In 1990, the figure was 15.8% and wait that reaches 61% in 2050. New generation. Grand View Research is an American consultant who wait That the GLP-1-based medication market triples its sales in China by 2030, from 1,430 million dollars last year to 4.7 billion. But of course, there are more competitors for Ozempic does not imply that Novo Nordisk is cross -arms. A few months ago, the Danish company announced that the results for Your new medicine, called CagrisemaThey were promising. In the essays, its new combination of Semaglutida and Cagrilintida It has shown a striking potential, with a medium weight loss of 15.7% in 68 weeks compared to 3.1% of the group that received placebo. In addition, they reached a development and manufacturing agreement of another compound known as UBT251 with a Chinese laboratory, United Biotechnology, which will be responsible for commercialization in China, Hong Kong, Macao and Taiwan. Everything based on miracles? It is evident that Novo Nordisk does not want to lose the train of the new generations of drugs that have exploited in popularity thanks to their status as miraculous compounds for weight loss. But not everything is needles, since Eli Lilly is already Testing pills with the same effects as the ‘Ozempicazo‘And more natural alternatives are being explored, such as diet, in the search for a “Natural Ozempic” Although, beyond the miracle, the closest thing to that “natural ozempic” is a balanced diet, exercise and good rest. The Holy Trinity of Healthy Lifeultimately. Images | Javier Quiroga, HAVEREDAS In Xataka | The Danish city paradox where the “formula” of Ozempic is manufactured. It is the epicenter of childhood obesity of the nation

Since his arrival, Zepbound was predestined to unseat Ozempic. The big question is why it is taking so long

by

In innovation, arriving first is a tremendous push when Develop a groundbreaking product. However, it is not a guarantee of success. This is a lesson that Danish pharmaceuticals Novo Nordisk is learning in their own meats. The last years have been marked by success the drugs of the GLP-1 family as Ozempic, Wegovy either Zepbound. The name refers to the peptide similar to glucagon-1 or LPG-1 (a hormone segregated in our body when we eat) since this type of formulas contain active compounds that “mimic” this hormone. In origin, drugs such as Ozempic or Zepbound were designed as diabetes treatment since one of the functions of the GLP-1 hormone It is to warn the pancreas of food entry to accelerate insulin production. However, the success of these treatments occurred due to a side effect also related to this hormone: and it is that the second of the messages transmitted by the LPG-1 is addressed to the brain, and it is the one that triggers the feeling of satiety. This is why agonist drugs of GLP-1 receptors also have a slimming effect. Companies that had compounds such as semaglutid New brands with which to market your compounds reorient to weight loss: Wegovy and Mounjaro. Throughout this process, the drugs of the Danish pharmacist, Ozempic and Wegovy, left with a kind of advantage, but there was a problem. The problem: the “recipe” of the American pharmaceuticals Lilly showed better results where these more treatments have highlighted, weight loss. The apparent reason is that just as the semaglutida is a simple agonist of the GLP-1 receptors, the tirzepatida is a double agonist of the GLP-1 receptors and of the receptors of the polypeptide gastric inhibitor or insulinotropic peptide dependent on glucose (GIP). If this were not enough, the magnitude of success reached an unexpected level, which had a serious involvement: Supply problems. This was not an exclusively economic but also health problem, we reconnected that before a product focused on weight loss, Ozempic was a diabetes treatment. A demand High and dissatisfied It is a great opportunity for the entry in play of new competitors, and this was precisely the panorama that the American pharmacist Lilly was found. A at odds Lilly launched Mounjaro in 2022 and success was vertiginous: the recipes shot and the new product seemed to quickly unseat their competitors. However, three years after launch it seems that the anticipated has not yet been Sorpasso. In fact, after a final stretch of 2024, some analysts wondered what was happening, why the success of Lilly’s formulas is postponing so much. However, In an article for Biospacethe consultants Gary Stibel and Riley McCarthy, of New England Consulting Group gave another key. For them the key to Ozempic’s persistence was in the marketing. In his article, Stibel and McCarthy indicate that Lilly attributed his difficulties when reaching the expected volume of sales to the high manufacturing costs and “fluctuating” levels of inventory in a high demand context. That is, that Lilly also managed to deal with the success of his own product. In the United States pharmaceuticals can announce more or less conventional medications that are only administered under medical prescription. According to these consultants, part of Ozempic’s success is due to these consumer -oriented campaigns. Although ultimately the choice of medication falls on the person in charge of signing the recipe, the patient’s weight can also be decisive. Regardless of campaigns of marketingit is difficult to overestimate the value of first such a lucrative market. Ozempic monopolized headlines and covers for months, and has become a few years in a kind of vulgarized brandthat is, a brand that has become an entire category of products. Something that in the short term can be a great advantage but long entails the erosion (even legal) of the brand itself. 2025 seems to draw a most hopeful panorama For the American pharmacist, but anticipating what will happen in the medium and long term is difficult for several reasons. Both pharmaceuticals continue to work with greater or lesser success in new formulas, double and even triple agonists that could unseat the products already settled. Laboratory results are difficult to predict and will depend in part with the future of these pharmacists. Another important factor is that we do not know the roof of this market. The calculations From the consulting firm Goldman Sachs they expect this roof will be reached at the beginning of the decade that comes, standing at about 120,000 million dollars around 2035. There is room for growth: according to the consultant the market volume in 2025 will be about 28,000 million dollars. This volume will have to be distributed with New formulaseven with generic alternativesthat could not take long to arrive after the threat that hits the Canadian patent of the Semaglutida. The expiration of the patents of these formulas will aggravate the need for the pharmaceuticals involved in introducing These new formulas that contribute something new to an increasingly competitive market. In Xataka | “Ozempic face”, “Ozempic language” and “Ozempic teeth”: the other very visible effect of consuming the medicine to lose weight Image | News Oresund

Generic medications have been trying to site Ozempic for years. And now they have found a shortcut in Canada

by

Something strange has happened with the patent that protects Ozempic In Canada. By mistake or by strategic decision, Novo Nordisk, the company responsible for developing the semaglutida, the compound on which the popular drug is based has been without paying the maintenance rates of this patent. An error of millions. The surprise jumped a few days ago. The chemist and expert disseminator in Pharmaceutical Industry Derek Lowe indicated Through an article in Science that the Danish pharmaceutical 370 dollars Canadians annual) that protects the compound on which drugs such as Ozempic and Wegovy are based. According to the Canada patent databasethe status of this patent is that of “expired and beyond the reversal period.” According to the Canadian Law, companies have a 12 -month grace period for claims and payment of late payments (another 150 Canadian dollars today). A period that would have already exceeded. Rubbing his hands. History began to reveal itself earlier this month. In an interview With the media specialized in pharmaceutical industry, Richard Saynor, CEO of Sandoz, talked about launching a generic medicine based on the peptide similar to glucagon 1 (LPG-1), the hormone to which the semaglutida to make its antidiabetic and slimming effect. As Lowe explains in his piece, the competition in the generic market can become “extremely beast.” Companies dedicated to this type of drugs seek as much as possible the patents, looking for failures that can invalidate them and thus be able to enter new markets. And today there are few markets as tempting as that of agonists of the GLP-1 hormone receptors such as Ozempic, Wegovy or Rybelsus. This family of drugs, oriented in its origin to treat diabetes, has achieved immense success for its slimming effect, triggering a whole revolution not only pharmaceutical, but also economic. A permeable border. An important detail mentioned by Saynor in its interview is that Canada is the second major semaglutidal market (after the United States). This would not be, speculate, because Canadians are great consumers of the drug, but is probably a consequence of the cross -border business. “There is clearly a dynamic, as with insulin, with business through the border,” Explains the director of Sandoz. “It will be interesting how this evolves,” he says. Evil of many … The expiration of the patent in Canada would not only affect Novo Nordisk but also could suppose a hard blow to its main competitor in the diabetes treatments and weight loss, the American Eli Lilly. The entrance into the market of a generic competitor would imply that the manufacturing company of Zepbound and Mounjaro. These drugs are based on the tirzepatida, a compound that acts as an analogue of the LPG-1 and also of another hormone called polypeptide gastric inhibitor or GIP. A mistake? An error? We began pointing out that patents are a fundamental pillar of the pharmaceutical industry which makes the doubt prevailing: why? It is difficult to know if everything is due to a simple error or a calculated strategy. “I never knew why this is sure that someone lost their job, but it doesn’t matter,” Saynor held in his interview. If it were a mistake, it would not be a mere mistake. According to Lowe explainsthe company showed in writing there by 2017 its reluctance to the payment of the maintenance rate of the Canadian patent of the Semaglutida. He boom Ozempic would not be given until years later, because perhaps the company was not able to anticipate success and considered the price of maintaining a patent in the North American country. In Xataka | In search of “natural ozempic”: what science knows about diets that simulate the effect of miracle medications Image | Rene Baker / Chemist4u

Psyllium went viral as a “natural alternative to Ozempic.” Reality is not so simple

by

Like any revolution, Ozempic came with promises and A hidden price. Then the side effects, the cost and the need for a medical prescription arrived. While its shadow is lengthened, an alternative option is born that does not need punctures through an millenary seed. The shell of a seed. What began as a traditional remedy in southern Asia today is a trend in Tiktok. More than 13,000 videos under the hashtag #psylliumhusk show how this fiber is incorporated recipes, Challenges and Tips for losing weightcalm appetite or improve digestion. But behind the viral phenomenon there is something much simpler: the Psyllium is the peel that surrounds the seeds of the ovata plantgo, a discreet but effective plant. Also known as Psilio, I know has used For years as soft laxative thanks to its ability to form mass and facilitate intestinal transit. The product can be consumed in dust, capsules or in its raw form, reminiscent of wood chips. Upon contact with water, this soluble fiber forms a thick gel. And it is precisely this viscosity that explains a good part of its benefits. Science behind. The secret of the Psyllium is how it reacts to water, since it absorbs and forms a thick gel. This process helps reduce appetite, improve intestinal transit and control cholesterol and blood sugar. In fact, an investigation He has confirmed ityou just have to consume between 10 and 15 grams daily to even reduce LDL cholesterol, the considered bad. Not everything is so simple. Although the enthusiasm in networks is understandable, experts ask for caution. First, for a security issue, since the Psyllium needs at least one liter of water for every 20 grams of fiber has pointed to The Guardian Lena Beal, spokesman for the Nutrition and Dietary Academy. The reason is none other than if it is not consumed without sufficient liquid, it can become a danger of suffocation or cause intestinal obstructions. It is not for everyone. It is not for everyone. Because it is natural, it does not mean that it is harmless. From Cleveland Clinic They do not recommend it in people with difficulties in swallowing, serious intestinal diseases (stenosis or crohn disease) or in cases of chronic digestive disorders. It is also advisable to take precautions if you are taking medication, since the fiber It can interfere. Natural Ozempic? Comparisons are always hateful, as the saying goes. The Psychlium shell does not alter the hormonal system as the GLP-1 agonists do. And although it can support weight loss, it does not do so in a powerful way or in all cases. More support. Because consuming more fiber is one of the most consistent recommendations of Modern nutritional science. In the end it is about incorporating improvements in the long -term diet, support that comes with a broader look on what it means to take care of yourself. Image | PGDP123 and Chemist4u Xataka | Ozempic and blindness, we have been on the track of an extremely rare adverse effect for months. Now the AEMPS has taken a step forward

Ozempic and blindness, we have been on the track of an extremely rare adverse effect for months. Now the AEMPS has taken a step forward

by

A few days ago the The United Kingdom warned on an unexpected effect associated with the use of Ozempic and treatments based on the same principle, the phenomenon of Ozempic Babies. Now the Spanish Agency for Medicines and Health Products (AEMPS) has also issued a statement but this time as a consequence of a very different effect. Adverse reaction. This week the AEMPS, the agency in charge of ensuring that the drugs meet the required standards, has issued A statement To warn of a very uncommon ocular adverse reaction “associated with treatments based on the semaglutida, the active compound of drugs such as Ozempic, Rybelsus or Wegovy. The notice occurs after the Committee for the Risk Assessment in Pharmacovigilance (PRAC) of the European Medication Agency (EMA) reviewed the risk of developing an ocular condition called Niana, which can cause loss of sudden vision. While the agency affects that the frequency of appearance of this type of eye problems is “very low”, it recommends that a sudden loss of vision is carried out an ophthanmological examination for Evaluate the possibility to interrupt the treatment. Noiana. Noiana is an acronym that refers to calls Previous ischemic optical neuropathiesNaion in English. These ailments are caused For the infarction of the optic nerve head. In other words, blood does not reach this eye region and a loss of vision occurs, which is typically fast but painless. It is an unknown and infrequent disease, not only in the context of those who follow a trailer treatment: its prevalence in the general population is approximately 10 cases per 100,000 inhabitants. A year on track. A year agoa study I found indications of the relationship between the treatments of Semaglutida and Niana. Indications such as those that gave rise to the evaluation by the Pract. The Committee reviewed clinical and preclinical essay data together with suspicion of adverse reactions, explains the AEMPS. This work resulted in the conclusion that trailer treatment can be associated with a risk of developing this disorder but indicate that with a very low frequency. The AEMPS speaks of “an increase in the risk of developing Niana of approximately double compared to people not exposed to this treatment. This corresponds to an additional case of NOIANA for every 10,000 patients treated with semagglutida for a year.” And what about the “other ozempic”? The AEMPS statement focuses on the drug -based drugs such as Ozempic, Rybelsus and Wegovy but does not indicate whether similar effects have been detected on similar treatments such as those based on the tirzepatida, such as Zepbound and Mounjaro. A medication with side effects. Like any drug, the semaglutida has a series of Contraindications and side effects. It should be remembered in this sense that the success of drugs such as Ozempic began when it was observed that this treatment against diabetes made those who followed it lost weight. In Xataka | “Ozempic face”, “Ozempic language” and “Ozempic teeth”: the other very visible effect of consuming the medicine to lose weight Image | Chemist4u / Amanda Dalbjörn

We have been seeing that Ozempic affects fertility. Now the United Kingdom has begun to take the “Ozempic Babies” seriously

by

Ozempic He began his career as a drug against diabetes but became one of the most popular medications worldwide when we realized that among its “side effects” was weight loss. Since then we have been detecting other possible effects, positive and negative but surely the most surprising of these is on its effects on fertility. Set deals with the phenomenon of the “Ozempic Babies” The United Kingdom warns. The authority responsible for regulating drugs and health products in the United Kingdom, MHRA (Medicines and Healthcare Products Regulatory Agency) warned a few days ago of a “new” side effect associated with the consumption of Ozempic, that of an increase in pregnancy probability. While this is the first time that the organism warns about the effect, the first news about this occurred More than a year ago. How it works. Ozempic is the brand with which Danish pharmaceuticals Novo Nordisk markets a diabetes treatment based on semaglutida. This compound also serves as a basis for Wegovyname under which the drug oriented to weight loss is marketed. To understand why the same compound can function as a treatment against diabetes and as a thinning we have to understand how it acts in our body. The semaglutida works as an agonist of the peptide receptors similar to glucagon-1 (LPG-1), that is, it works as an analogue of this key hormone in the digestive process. When we eat our body naturally secretes the GLP-1 hormone to transmit two messages. The first to the pancreas, so that it begins to segregate insulin with which to metabolize the sugars of the food. The second to the brain, so that this knows that we are satiated. Drugs like Zepbound and Mounjaro They act similarlyalthough the tirzepatida on which they are based works as a double analogue of LPG-1 and GIP hormones (gastric inhibitor polypeptide). Ozempic Babies. A little over a year ago, dozens of women in treatment with any of these medications They started informing of a strange phenomenon: They were becoming pregnant despite being considered infertile or despite resorting to contraceptives. This phenomenon was soon baptized as the “Ozempic Babies“,” Ozempic babies. “ How do you do it? Since the phenomenon began to document, many wondered how it was possible. There are two mechanisms (alternative or complementary) that can explain this phenomenon. The first has to do with contraceptives, specifically with oral contraceptives. One of Ozempic’s effects is that of slow down our digestionwhich in turn makes nutrients and other compounds absorb more slowly. In the preparation of an oral treatment, absorption speed is an important variable to take into account. Drugs such as contraceptives are designed for specific speeds, if these change too much, treatment can lose efficacy. He Another mechanism that could explain this phenomenon has to do with its slimming effect. As experts also highlight, there is an inverse relationship between obesity and overweight and fertility. It is possible, that by facilitating weight loss the drug is also contributing to increasing the probabilities of pregnancy. A double problem. The problem is double since it not only implies a greater probability of an unwanted pregnancy; also because this type of treatments They are contraindicated Not only for pregnant women, but also in those who seek to be. According to the recommendations, who wants to find a pregnancy should interrupt these treatments At least two months In advance to allow our body to return to normal and avoid unnecessary risks in a process as complex as gestation. Positive effects and negative effects. The “fever” by Ozempic and the drugs of its class began with a side effect: a medication aimed at treating diabetes made those who consumed it lose weight. The demand for these compounds has allowed us to find other possible Side effectspositive and negative, on which we have a greater or lesser degree of certainty. Possible adverse effects documented by the manufacturer itself can find problems such as aggravation of diabetic eye disease, potential allergic reactions and a variety of gastrointestinal symptoms, from nausea to constipation. However, since it also began to be used We have found indications on other possible effects. Some positives such as helping the fight against addictions or possible effects on renal health either cardiovascular. In the negative face we have also found indications of loss of hair and eye problems. In Xataka | “Ozempic face”, “Ozempic language” and “Ozempic teeth”: the other very visible effect of consuming the medicine to lose weight Image | Chemist4u / Camylla Battani

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.